On Chemball
My Chemball
+86-571-8627 3270
BrightGene Bio-Medical Technology Co., Ltd.
BrightGene Bio-Medical Technology Co., Ltd.
23 YRS
Jiangsu, China
Main Products:
Obeticholic Acid / Tebipenem Pivoxil / Laninamivir Octanoate / Dienogest / Carboprost Tromethamine / Fish Oil / Eldecalcitol / Oseltamivir Phosphate / Sugammadex / Pimecrolimus / Spinosyn D / Entecavir
Jiangsu, China
Send Email
Sending...
Thank You！
Your requirement has been sent, we will contact you quickly!
Sent Failed！
Try again!
ABOUT US
BrightGene Bio-Medical Technology Co., Ltd. (stock abbreviation: Borui medicine; Stock Code: 688166), is a R & D driven high-tech pharmaceutical company, committed to R & D and production of original new drugs and high-end generic drugs, and providing patients with products with excellent value with professional product development ability and commercialization ability.
With the goal of "continuous innovation and health protection", Borui medicine is looking for solutions for unmet clinical needs. After years of continuous research and development, Bo Rui has made breakthroughs in the field of targeted therapy and immunotherapy for tumors, as well as the treatment of fatty liver and diabetes, and many new original drugs have entered or will soon enter clinical research. Borui pharmaceutical has successfully developed high-end generic drugs such as irebrin, trobetidine and fondaparinux sodium, and has connected the whole industrial chain from "starting materials → difficult intermediates → characteristic APIs → preparations". A number of pharmaceutical intermediates and API products independently developed and produced by the company have been registered with DMF in major international standardized market countries such as the United States, Europe, Japan and South Korea and China, and have been cited by customers. The company has established a product line with global competitive advantages in the fields of anti-tumor, super antibiotics and intravenous iron supplement.
With strong R & D strength as the cornerstone of development, Borui pharmaceutical has achieved rapid development and become a leading enterprise and international pioneer in China's pharmaceutical industry by relying on global registration ability and commercialization ability and cGMP production quality system in line with international standards.
The GMP production quality system of Borui pharmaceutical has passed the official certification of many countries and regions such as FDA of the United States, the official of the European Union drug administration, PMDA of Japan and MFDs of South Korea and the new version of GMP certification in China, so as to ensure the drug quality with international high-standard drug quality management norms and strict drug production quality management system. The company's products have been sold in many countries and regions around the world, and the main products occupy a large market share. We look forward to more cooperation with industry partners to achieve win-win results and benefit patients all over the world.
Borui pharmaceutical adheres to "people-oriented", provides broad development space for all kinds of talents, provides patients with high-quality, effective, safe and reliable cost-effective drugs, and creates a warm and healthy social living environment. Based on China and looking at the world, Borui pharmaceutical strives to build a market integrating R & D, production, technical services Sales as one of the more internationally competitive high-tech pharmaceutical enterprises.
Basic Information
Tax ID
91320000731789594Y
Country/Region
Jiangsu, China
Year Established
2001
Registered Capital
CNY 410 Million
Business Type
Manufacturing
Total Employees
100-500 people
Quality Management Certificate
SFDA-GMP
Total Annual Revenue
CNY 748 Million
Enterprise Ownership
Private Owned
Is This Your Own Factory
Yes
Summary Up
BrightGene has made breakthroughs in the field of targeted therapy and immunotherapy for tumors, as well as in the treatment of fatty liver and diabetes, and many new original drugs have entered or will soon enter clinical research
PLANT LOCATION
COMPANY ALBUM
